Neurocrine: INGREZZA franchise growth
Neurocrine’s Q2 outlook gives INGREZZA sales guidance of $2.825B–$2.875B. A $2.85B midpoint focuses on the named neuroscience franchise.
Neurocrine Biosciences / NBIXPublic biotechEarningsDate to watch
What matters
Watch product sales, guidance and cash needs alongside the headline result. Company filings and the earnings release provide the primary evidence.
- Refresh later guidance; this threshold uses the Q2 source snapshot.
Primary evidence
Reporting date unconfirmed — research candidate
Neurocrine Q2 2026 results and financial guidanceCompany source
Potential outcome market
Will Neurocrine 2026 INGREZZA net product sales exceed $2.85 billion?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.